ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy.

摘要: Abstract Excision repair cross-complementation group 1 (ERCC1) is a highly conserved protein and an essential member of the nucleotide excision pathway. DNA important mechanism for resistance to platinum-based chemotherapy. Previous studies have shown that ERCC1 gene expression associated with clinical outcome platinum chemotherapy in variety cancers. Recently, 2 common polymorphisms been described. The first single polymorphism at codon 188 causes C-->T change but codes same amino acid, asparagine. This may be differential expression. second also signal 3'-untranslated region affect MRNA stability. We hypothesized these assessed relationship between 106 patients advanced refractory colorectal cancer. found significant 118 outcome. Patients C/C genotype had median survival 15.3 months (95% CI, 6.0-12.1) 11.1 5.8-16.2) those C/T T/T genotypes, respectively. useful predictor cancer treated